大型多元整合医疗系统内非肌层浸润性膀胱癌初始治疗中膀胱内治疗的使用质量与差异
该研究为回顾性队列研究,纳入2001年1月至2015年6月在Kaiser Permanente Southern California诊断为非肌层浸润性膀胱癌的5386例患者,分析术后膀胱内化疗、诱导卡介苗(BCG)免疫治疗及任何膀胱内治疗的使用情况。结果显示41%的患者接受了膀胱内治疗,术后化疗使用逐年增加(OR=1.16,95%CI:1.07-1.25),BCG使用与肿瘤特征强相关,不同泌尿外科医生间治疗差异明显。
要点
- 2001至2015年新诊断NMIBC患者中41%接受了膀胱内治疗。
- 术后化疗使用随时间显著增加,OR=1.16(95%CI:1.07-1.25)。
- 高级别或原位癌患者更可能接受BCG(OR=10.10,95%CI:8.39-12.16)。
核心结论
- 在大型多元整合医疗系统内,NMIBC初始治疗在不同泌尿外科医生之间存在显著差异,该差异在考虑肿瘤、患者和提供者特征后仍存在;结果提示质量改进项目有减少不必要治疗差异并改善患者照护的相当机会。
研究设计与样本
- 回顾性队列研究,纳入2001年1月至2015年6月在Kaiser Permanente Southern California诊断为NMIBC的5386例患者,使用电子健康数据识别治疗结局及患者、提供者和肿瘤特征。
- 采用广义线性混合模型估计多变量比值比(OR)和95%置信区间(CI),以二分类结局为因变量、泌尿外科医生为随机效应。
主要发现
- 2001至2015年,41%的新诊断NMIBC患者接受了膀胱内治疗。
- 术后化疗使用在该期间显著增加(每年OR=1.16,95%CI:1.07-1.25)。
- 高级别或原位癌肿瘤患者更可能接受BCG(OR=10.10,95%CI:8.39-12.16)。
- 按性别或种族/民族发现的治疗差异较少,但观察到按年龄存在差异。
- 不同泌尿外科医生间治疗差异较大,部分医生从不将膀胱内治疗作为初始治疗的一部分,而另一些医生几乎总是使用。
关键数值与推荐
- 术后化疗使用:每年OR=1.16,95%CI:1.07-1.25。
- 高级别或原位癌肿瘤患者接受BCG:OR=10.10,95%CI:8.39-12.16。
- 术后化疗使用的组内相关系数=0.52;BCG免疫治疗使用的组内相关系数=0.11。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine treatment variability, disparities, and quality among newly diagnosed nonmuscle invasive bladder cancer (NMIBC) patients, and to identify factors associated with treatment use in a large, diverse integrated delivery system. METHODS: Retrospective cohort study of 5386 NMIBC patients diagnosed between January 2001 and June 2015 within Kaiser Permanente Southern California. Electronic health data were used to identify treatment outcomes and patient, provider, and tumor characteristics. Outcomes were use of (1) postoperative intravesical chemotherapy, (2) induction Bacille Calmette-Guérin (BCG) immunotherapy, and (3) any intravesical therapy. Multivariable odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using generalized linear mixed models with a binary outcome and urologist as a random effect. RESULTS: From 2001 to 2015, 41% of newly diagnosed NMIBC patients were treated with intravesical therapy. Postoperative chemotherapy use increased significantly over this period (OR per-year = 1.16, 95% CI: 1.07-1.25). BCG use was strongly associated with tumor characteristics: patients with high-grade or carcinoma in situ tumors were more likely to receive BCG (OR = 10.10, 95% CI: 8.39-12.16). Few treatment differences were found by sex or race/ethnicity, but were observed by age. Wide treatment variability across urologists was observed, with some urologists never using intravesical therapy as part of initial treatment while others almost always used it. Differences across urologists accounted for more variability in postoperative chemotherapy (intraclass correlation coefficient = 0.52) than BCG immunotherapy (intraclass correlation coefficient = 0.11) use. CONCLUSION: Substantial variability in initial treatment of NMIBC was observed across urologists, accounting for tumor, patient, and provider characteristics. Results suggest a considerable opportunity for quality improvement programs to reduce unwanted treatment variability and improve care for patients.
引用
- Danforth KN, Sidell MA, Luong TQ, et al. Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer Within a Large, Diverse Integrated Delivery System. Urology. 2019. PMID: 31129191. doi:10.1016/j.urology.2019.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。